[HTML][HTML] Epstein-Barr virus-associated post-transplant lymphoproliferative disorders: beyond chemotherapy treatment
S Shahid, SE Prockop - Cancer Drug Resistance, 2021 - ncbi.nlm.nih.gov
Post-transplant lymphoproliferative disorder (PTLD) is a rare but life-threatening
complication of both allogeneic solid organ (SOT) and hematopoietic cell transplantation …
complication of both allogeneic solid organ (SOT) and hematopoietic cell transplantation …
Successful obinutuzumab administration after rituximab discontinuation due to intolerance in patients with hematologic disorders
T Schieber, A Li, J Lundberg, T Wiczer… - Blood …, 2023 - ashpublications.org
Rituximab has transformed the treatment of multiple hematologic disorders over the past 2
decades, leading to higher response rates and longer survival; however, drug …
decades, leading to higher response rates and longer survival; however, drug …
Successful treatment of hairy cell leukemia variant with obinutuzumab
D Al-Sarayfi, FO Meeuwes, TO Munnink, W Plattel… - Annals of …, 2022 - Springer
A 70-year-old male presented with pancytopenia and massive splenomegaly. Bone marrow
examination and flow cytometry showed an extensive infiltration by hairy cell leukemia …
examination and flow cytometry showed an extensive infiltration by hairy cell leukemia …
Safe administration of obinutuzumab to rituximab-intolerant patients
K Manos, A Grigg - Leukemia & lymphoma, 2021 - Taylor & Francis
Rituximab, the first anti-CD20 antibody incorporated into routine practice, is a type I chimeric
murine/human antibody which predominantly acts via complement-dependent cytotoxicity …
murine/human antibody which predominantly acts via complement-dependent cytotoxicity …
[PDF][PDF] Successful Obinutuzumab Use after Rituximab Discontinuation due to Intolerance in Patients with Hematologic Disorders
T Schieber, A Li - researchgate.net
Author contributions and disclosures: TS designed research, performed research,
contributed vital new reagents or analytical tools, analyzed data, and wrote the paper. AL …
contributed vital new reagents or analytical tools, analyzed data, and wrote the paper. AL …
[HTML][HTML] Rituximab-induced Serum Sickness in Lymphoma: A Case Report
B Navarro-Matilla, A Ramirez-Garcia… - … Myeloma and Leukemia, 2021 - Elsevier
Clinical Practice Points• Rituximab-induced serum sickness (RISS) was not reported in
clinical trials and it is believed to be extremely rare in patients with hematologic …
clinical trials and it is believed to be extremely rare in patients with hematologic …